A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin in Patients With Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination With Idasanutlin in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Idasanutlin (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 25 Jul 2019 This trial has been completed in Germany , according to European Clinical Trials Database.
- 20 Jun 2019 Status changed from active, no longer recruiting to discontinued.